BrightGene Bio-medical Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (512) 6255-1801 6255-1767 +86 13812696362 | |||
![]() |
kevinwan@bright-gene.com kevinwan0203@gmail.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2001 | ||||
chemBlink standard supplier since 2009 | ||||
Taizhou Crene Biotechnology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (576) 8881-3233 8820-5808 +86 13396860566 | |||
![]() |
order@pharm-intermediates.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2011 | ||||
chemBlink standard supplier since 2009 | ||||
BOC Sciences | USA | Inquire | ||
---|---|---|---|---|
![]() |
+1 (631) 485-4226 | |||
![]() |
info@bocsci.com | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2010 | ||||
Changzhou Fang Nan Medical Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (519) 8528-3268 8528-3269 +86 13764769395 | |||
![]() |
sales@alnovapharm.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2014 | ||||
chemBlink standard supplier since 2015 | ||||
Hangzhou Molcore Biopharmatech Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (571) 8102-5280 | |||
![]() |
sales@molcore.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2010 | ||||
chemBlink standard supplier since 2017 | ||||
Sichuan Taienkang Pharmaceutical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 15102825326 | |||
![]() |
sales@taienkangpharma.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2020 | ||||
chemBlink standard supplier since 2024 | ||||
Classification | Biochemical >> Inhibitor >> G protein coupled receptor(GPCR & G Protein) >> S1P receptor conditioner |
---|---|
Name | Siponimod |
Synonyms | 1-(4-[1-[(E)-4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl-benzyl)-azetidine-3-carboxylic acid; BAF 312 |
Molecular Structure | ![]() |
Molecular Formula | C29H35F3N2O3 |
Molecular Weight | 516.60 |
CAS Registry Number | 1230487-00-9 |
SMILES | CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O |
Solubility | Insoluble (1.7E-4 g/L) (25 ºC), Calc.*, 10 mM (DMSO) (Expl.) |
---|---|
Density | 1.24±0.1 g/cm3 (20 ºC 760 Torr), Calc.* |
Index of Refraction | 1.571, Calc.* |
Boiling Point | 602.0±65.0 ºC (760 mmHg), Calc.* |
Flash Point | 317.9±34.3 ºC, Calc.* |
* | Calculated using Advanced Chemistry Development (ACD/Labs) Software. |
Hazard Symbols |
|
---|---|
Hazard Statements | H302-H315-H320-H335 Details |
Precautionary Statements | P264-P270-P301+P312-P330 Details |
SDS | Available |
Siponimod is a selective modulator of sphingosine-1-phosphate receptor subtypes 1 and 5. It was developed as a treatment for secondary progressive multiple sclerosis (SPMS) and has demonstrated efficacy in reducing the risk of disability progression. The compound was discovered through targeted medicinal chemistry efforts aimed at enhancing receptor selectivity and optimizing pharmacokinetic properties to enable central nervous system penetration. The synthesis of siponimod involves a series of chiral transformations to ensure the desired enantiomeric purity, which is critical for its biological activity. The key step in the synthesis involves the construction of the core structure via asymmetric catalysis followed by functional group modifications to introduce the required side chains. This pathway was optimized to maximize yield and minimize impurities, resulting in a scalable process suitable for industrial production. Siponimod's primary application lies in its use for managing SPMS, a progressive form of multiple sclerosis characterized by accumulating neurological deficits. By selectively modulating sphingosine-1-phosphate receptors, siponimod reduces lymphocyte egress from lymph nodes, thereby decreasing neuroinflammation. This mechanism helps preserve neurological function and delay the progression of disability in patients with SPMS. |
Market Analysis Reports |
List of Reports Available for Siponimod |